usage in these individuals. 18 The impact of FQ on the development of resistance in MTB has mostly been discussed in the context of CAP. [45] [46] [47] [48] A recent meta-analysis evaluating the association of prior FQ usage and the development of resistance in MTB reports a three-fold higher risk of FQ-resistant MTB in patients prescribed FQ before TB diagnosis. 40 Prolonged FQ exposure (defined as more than 10 days of treatment), or multiple FQ prescriptions have been highlighted as significant risk factors for the development of FQ resistance in MTB. 45, 49, 50 Evidence such as this has led to strong recommendations for avoiding FQ in national CAP guidelines. 51 Despite these recommendations, the majority of national CAP treatment guidelines in TB-endemic countries continue to include FQ as first-line treatment due to the fact that high global resistance rates amongst respiratory pathogens to alternative agents, including macrolides, limit options. 48 A recent review of global FQ resistance rates reports a much higher odds ratio for FQ resistance in MDR-TB as compared to non-MDR-TB. 52 Such resistance is associated with the use of a secondline therapy including FQ in the management of MDR-TB 31, 52, 53 and is attributed to inadequate treatment protocols. 54, 55 Hence strict supervision of second-line therapy is recommended. 56 These recommendations are supported by a recent study from Taiwan, where for both primary FQ resistance and acquired FQ resistance, rates decreased significantly following the implementation of a successful directly observed therapy DOT-Plus programme. 57 
Impact of FQ resistance on MTB treatment
Considerable data are available reporting delayed sputum culture conversion and treatment failure in TB patients with FQ resistance. 51, [58] [59] [60] Resistance to ofloxacin has been linked with delayed culture conversion in a recent study from Pakistan. 61 An earlier systematic review of 36 trials reporting end-of-treatment or follow-up outcomes for MDR-TB patients had reported FQ resistance as being associated with poor outcomes (including any of death, default, transfer out, or treatment failure). 62 While the results of this review may have been biased due to trial and outcome heterogeneity, the findings are nevertheless a cause for concern given the significant role of FQ in MDR-TB treatment. These findings are consistent with another more recent study that analysed individual patient data from 31 published cohorts of patients with MDR-TB and extensively drug-resistant TB (XDR-TB). 63 Using data on drug sensitivity, treatment, and outcome (cure/treatment completion, failure/relapse/death), this study reports in vitro susceptibility to second-line drugs including FQ as being consistently and significantly associated with higher odds of treatment success. 63 More worrisome is the emergence of XDR-TB strains in patients on second-line treatment. A study performed in nine countries reported an XDR acquisition rate of 17% in patients with baseline FQ resistance. 53 Attempts to shorten the duration of first-line TB therapy have led to the inclusion of FQ in shorter, 4-month regimens. 64 Recent phase 3 trials of three such regimens, two containing moxifloxacin and the third gatifloxacin, do not show non-inferiority of the shorter regimens, indicating that shortening treatment to 4 months was not effective. [65] [66] [67] Moreover, these regimens have raised concern about the efficacy in areas with high FQ resistance, wherein treatment failure and the emergence of MDR-TB strains is likely. In contrast, excellent outcomes for a 9-month gatifloxacinbased regimen have increased optimism for improved and shorter MDR-TB management. [68] [69] [70] [71] However, given that FQ resistance was the strongest risk factor for a bacteriologically unfavourable outcome, the protocol needs to be evaluated in high FQ-resistant TB settings. 71 Whether a higher dose of newer FQ may still be successful in such settings requires investigation.
Cross-resistance to newer FQ and other second-line TB drugs
The use of newer FQ for the management of ofloxacin-resistant MDR-and XDR-TB is recommended. 72 Nevertheless, a significant proportion of ofloxacin-resistant strains are also resistant to the newer FQ. 36, 73, 74 Newer FQ should thus not be used indiscriminately for drug-resistant TB in high FQ resistance settings without prior susceptibility testing. 59, 75 Additionally FQ resistance has Second-generation Ofloxacin 1.0-2.0 Has been used as first-and second-line agent 8, 9 Recommended for inclusion in MDR-TB regimens Not currently recommended as first-line agent Ciprofloxacin 0.5-4.0 In vitro activity, but may lack in vivo efficacy. Trials as first-line agent for drug-sensitive TB resulted in higher relapse rates 10, 11 Not recommended Levofloxacin 1.0 More efficacious than ofloxacin for second-line treatment, but ofloxacin resistance may lead to treatment failure 8, 12 Recommended for inclusion in MDR-TB regimens Not currently recommended as first-line agent a First-and second-line, where mentioned, refer to standard regimens. First-line treatment for drug-sensitive TB: 2 months of HRZE + 4 months of HR (where H = isoniazid, R = rifampicin, Z = pyrazinamide, and E = ethambutol); 4 months of HRE is used in settings with high isoniazid resistance. Second-line treatment regimens are used for MDR-TB; it is recommended that these include at least a fluoroquinolone in addition to pyrazinamide, an injectable anti-TB drug, ethionamide (or prothionamide), and either cycloserine or para-aminosalicylic acid. 7 been reported to have a much higher co-resistance to other firstline and second-line agents used in the treatment of TB. 76 
Healthcare system constraints driving FQ resistance
While a number of factors may contribute to FQ resistance in the community, resistance in MTB is driven to a significant extent by poor FQ pharmacokinetic/pharmacodynamic (PK/PD) exposure in patients with active disease. 77 Such faulty dosing stems as much from insufficient implementation of regulations related to the use of FQ in TB or CAP, as from inadequate regulations for controlling drug quality and antimicrobial usage in the community.
Inappropriate TB treatment by inadequately trained professionals, physicians, pharmacists, and allied health workers, particularly in the private sector, is common in weak healthcare systems. 78 Many TB patients receive either unwarranted FQ therapy or treatment with alternative FQ with poor activity. In high TB burden countries, up to 30% of patients receive ciprofloxacin, 79 an agent not recommended for use in TB due to narrow mutant prevention windows. 50 Both counterfeit as well as substandard FQ preparations are rife in many developing countries. 80 The use of counterfeit antibiotics has been reported from Nigeria, India, Bangladesh, Burma, Cameroon, Vietnam, Cote d'Ivoire, and several other countries.
81 Factors contributing to the easy availability of substandard preparations include inadequate approval and regulatory policies and improper manufacturing practices and quality assurance in manufacturing. 82 In India alone, >60 000 brands of various drugs are marketed, but are not registered, 83 therefore not subject to any policies that may exist. In such systems, antibiotics are often used as a substitute for poor policy control and regulations and to fill practice gaps in preventing infections, e.g., vaccine coverage, hygiene practices, and health education of communities. 84 Such usage is promoted by physician behaviour and malpractice. Prescriptions for monetary benefits or for incentives offered by manufacturers or vendors of counterfeit FQ preparations abound in high TB burden countries. 83 Hospitals may also rely on pharmaceuticals for the generation of income for employees. 78 Prescription malpractice also includes offering more expensive brands to well-off patients and cheaper brands to the poor or uninsured, resulting in sustained sales of counterfeit drugs of varying quality.
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The over-the-counter (OTC) sale of drugs is in fact an important predictor of FQ-resistant MTB. 85 TB patients, mostly belonging to the lower socioeconomic strata of society and unable to afford costly private physician consultations, 86 self-medicate with better-known (and pharmacy-driven) antibiotics including those for CAP. 87 In the generation of FQ-resistant MTB, the contribution of FQ in the non-healthcare-associated environment is also significant. This includes the presence of small amounts of FQ in the food chain as a result of unregulated use in farm animals, as growth supplements in medicated feeds, 88 in aquaculture, 89 in domestic water contaminated with farm effluents, 90 and in adulterated food products. 91 Moreover in high TB burden countries where farming is often the principal occupation, a number of patients have direct contact with sick animals on therapeutic veterinary FQ. Despite the US Food and Drug Administration ban on the veterinary use of enrofloxacin, 92 it is still used in countries with weak healthcare systems. 93 Oxolinic acid and flumequine are other quinolones in common use by farms, veterinarians, and in aquaculture that have documented cross-resistance with FQ for human use. 92 An equally important contributor to the increased consumption of FQ (hence resistance) in weak healthcare systems is the lack of availability of reliable antibiotic susceptibility data, 84 both for MTB and for other bacterial infections. Inadequate surveillance strategies, poor quality laboratory data, and limited awareness of resistance epidemiology among healthcare workers lead to the overuse of FQ in CAP, assuming beta-lactam or tetracycline resistance. The generation of such data is essential for creating awareness and better therapeutic regimens.
The cost of increasing FQ resistance in weak healthcare systems
We have described the many inadequacies of weak healthcare systems leading to FQ resistance in TB. Here, we outline the burgeoning inadequacies in weak healthcare systems that in turn result from FQ resistance in MTB. The operational goals of healthcare systems are health, responsiveness, and financial risk protection for the community. 94 Increasing FQ resistance in MTB affects each of these goals directly or indirectly.
Financial impact
The treatment of several diseases requires out-of-pocket expenditure for patients and TB is no different. Despite the efforts of the World Health Organization and the Stop TB Partnership toward DOTS and DOTS-Plus coverage in high TB burden countries, weak healthcare systems are unable to ensure 100% treatment coverage; the contribution of the private sector in such care is thus considerable. As highlighted above, FQ resistance may result in either poly or XDR-TB. The cost of XDR-TB treatment, prolonged regimens, unaffordable medications, and surgery are still borne by patients to a considerable extent. Adding to this cost are the emotional and social costs of depression due to prolonged illness, poverty, and social isolation.
Impact on health
Any antibiotic resistance directly affects population health through adding to the microbial resistance gene pool and making eradication/control difficult. Health equity is also affected by a mismatch of resources against the greatest need. FQ are increasingly prescribed for other infections for which other effective treatments exist, 95 in contrast to TB, for which a limited number of anti-TB drugs are known.
Impact on responsiveness
Public health responsiveness to manage community expectations is affected directly as a consequence of resistance. Communities now know TB to be a treatable disease, however expectations are not met when XDR-TB or MDR-TB with FQ-only resistance (pre-XDR) fail treatment. Moreover, there are increasingly fewer resources to meet other expectations such as contact tracing and prevention in such cases.
All such constraints on the healthcare system lead to sustained transmission and an increasing incidence of FQ-resistant TB.
• Impl ementation of FQ DST prior to initia ting F Q-based first-or second-line TB 
Approach to the problem of FQ-resistant MTB
Keeping in view the manifold and system-wide causes of the increase in FQ resistance, the response to contain resistance must also be system-wide. The development and approval of policies to overcome the aforementioned constraints are the first steps required. These are summarized in Figure 1 .
Addressing workforce shortages and training inadequacies are the next steps in strengthening systems. Initiatives must involve all components of the healthcare system, agriculture, aquaculture, and animal health following the model of the One Health Initiative, which proposes that the integration of human with veterinary and environmental health interventions enhances disease control efforts. 96 However, in weak healthcare systems, the challenge is the implementation of policies. To facilitate implementation, policymakers must also ensure cultural acceptability, economic feasibility, and endorsement by the healthcare community. The allocation of resources, redistribution of finances, and recruitment of public, private, and international funders, as well as stakeholder engagement, are essential to improve policy responsiveness. If these steps can be taken by policymakers at a national level, healthcare systems can be improved to incorporate stewardship of FQ usage.
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